Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus Obinutuzumab in First-line MZL
NCT06592170Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Countries
- 1
- Sponsor
- The First Hospital of Jilin University
- Modality
- Small Molecules
- Drugs
- linperlisib
- Conditions
- marginal zone lymphoma (MZL)
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in marginal zone lymphoma (MZL), sponsored by The First Hospital of Jilin University. Primary endpoint: Complete Response at 6 months. Started Aug 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental group
Linperlisib + Obinutuzumab induction followed by Linperlisib maintenance
03
Who it enrols
Adult patients with newly diagnosed marginal zone lymphoma (MZL) who have not received prior anti-tumor treatment, with measurable disease and adequate organ function.
04
Endpoints
Primary
Complete Response
Secondary
Objective Response Rate
Duration of Response
Adverse Events
Disease Control Rate
Progression-Free Survival
Beyond the preview
Go deeper on NCT06592170.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592170.